J.P. Morgan Resumes Coverage on Warner Chilcott (WCRX) with an Overweight
More News related to WCRX
- Oppenheimer Starts Mylan (MYL), Warner Chilcott (WCRX) at Outperform
- Caris & Co Upgrades Warner Chilcott (WCRX) to Buy
- Notable Analyst Rating Changes 02/01: BIDU, ALV, G, ARG, ASH Upgraded; CPF, M, LZ, COGT, WCRX Downgraded
- Morgan Stanley Downgrades Warner Chilcott (WCRX) to Equalweight
- Warner Chilcott (WCRX) Issues Mixed Guidance for 2010
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
J.P. Morgan resumes coverage on Warner Chilcott (Nasdaq: WCRX) with an Overweight rating. Price target $27.
To see more analyst ratings on WCRX Click Here.
Warner Chilcott Limited, a specialty pharmaceutical company, engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in womens healthcare and dermatology segments primarily in the United States.
Related Categories
New CoverageStocks Mentioned
+0.30Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
